Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for ion channels.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the channel in its native membrane environment in open, closed and inactivated forms and the ensemble virtual screening accounting for conformational mobility in each of these states. Tentative binding pockets are considered inside the pore, in the gating region and in the allosteric locations to cover the whole spectrum of possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q01668
UPID:
CAC1D_HUMAN
Alternative names:
Calcium channel, L type, alpha-1 polypeptide, isoform 2; Voltage-gated calcium channel subunit alpha Cav1.3
Alternative UPACC:
Q01668; B0FYA3; Q13916; Q13931; Q71UT1; Q9UDC3
Background:
The Voltage-dependent L-type calcium channel subunit alpha-1D, known as Cav1.3, plays a pivotal role in the entry of calcium ions into excitable cells. It is crucial for various calcium-dependent processes such as muscle contraction, hormone release, and cell division. Cav1.3 is part of the 'high-voltage activated' (HVA) group and is sensitive to blockage by dihydropyridines.
Therapeutic significance:
Cav1.3 is implicated in Sinoatrial node dysfunction and deafness, characterized by congenital deafness and episodic syncope, and in Primary aldosteronism with seizures and neurologic abnormalities. These associations highlight its potential as a target for therapeutic strategies aimed at treating these conditions.